Related Experiment Video

Updated: Jun 3, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Medical management of hypertrophic cardiomyopathy

Jesse J Naghi1, Robert J Siegel

  • 1Division of Cardiology and the Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Reviews in Cardiovascular Medicine
|March 11, 2011
PubMed

Insights

Hypertrophic cardiomyopathy (HCM) is a genetic heart condition causing left ventricular hypertrophy. Medical treatments aim to manage symptoms and reduce the risk of sudden cardiac death (SCD) in HCM patients.

Area of Science:

  • Cardiology
  • Genetics
  • Internal Medicine

Background:

  • Hypertrophic cardiomyopathy (HCM) is the most prevalent inherited cardiomyopathy.
  • It stems from mutations in genes encoding sarcomeric proteins, leading to left ventricular hypertrophy.
  • HCM presents with diverse symptoms, from mild discomfort to life-threatening events like sudden cardiac death (SCD).

Purpose of the Study:

  • To review the current medical treatment landscape for hypertrophic cardiomyopathy.
  • To highlight therapeutic strategies for symptom management and risk reduction in HCM.
  • To provide an overview of medications used in HCM management.

Main Methods:

  • Literature review of medical treatments for HCM.
  • Analysis of therapeutic approaches for symptom control and SCD risk mitigation.
  • Compilation of commonly prescribed medications including beta-blockers, calcium channel blockers, amiodarone, disopyramide, and angiotensin receptor blockers.

Main Results:

  • Medical therapy is the primary approach for the majority of HCM patients.
  • Various medications are employed to alleviate symptoms such as dyspnea and chest pain.
  • Treatment strategies focus on both symptomatic relief and preventing sudden cardiac death.

Conclusions:

  • Current medical treatments for HCM focus on symptom management and reducing SCD risk.
  • A range of pharmacological agents are utilized to control HCM symptoms.
  • Ongoing research and clinical practice continue to refine HCM treatment protocols.

More Related Videos

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...